Forteo Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing patients on Forteo (teriparatide) for osteoporosis, you may have heard from patients who are struggling to fill their prescriptions. This briefing provides an up-to-date clinical summary of the Forteo availability landscape in 2026—so you can set realistic expectations and proactively address barriers for your patients.

Current Supply Status: No FDA Shortage

As of early 2026, Forteo is not listed on either the FDA drug shortage database or the ASHP shortage database. Both brand-name Forteo (Eli Lilly) and generic teriparatide (Teva, Apotex, Alvogen/Bonsity) are in active production and distribution. The supply chain for teriparatide is not experiencing manufacturing or raw material disruptions.

However, patient access challenges are real and persistent. They are structural rather than supply-based, rooted in specialty distribution logistics, cold chain requirements, and payer-imposed barriers.

Key Developments Affecting Access in 2024–2026

2023: First true generics approved. Teva and Apotex received FDA approval for generic teriparatide injection in November 2023, following Lilly's patent expiration. Bonsity (Alvogen/Pfenex) had been available since mid-2020 but is a 505(b)(2) product rather than a true generic.

Q1 2025: Lilly labeling change. Eli Lilly updated Forteo pen labeling from 600 mcg/2.4 mL to 560 mcg/2.24 mL. No change to dosing or clinical effect. However, updated NDC numbers caused temporary billing discrepancies at pharmacies and with payer adjudication systems, creating dispensing confusion that has mostly resolved by mid-2025.

2025–2026: Generic formulary penetration increasing. Multiple payers have moved generic teriparatide to preferred formulary status, often placing brand Forteo at higher tiers or requiring PA exceptions. Prescribing as "teriparatide" (rather than Forteo DAW) may improve formulary access and reduce patient copays.

Why Patients Can't Find Forteo at Their Local Pharmacy

The most common patient complaint—"my pharmacy doesn't have it"—is almost never a manufacturing shortage. It reflects the economic reality of stocking a specialty biologic:

Forteo must be refrigerated (2–8°C). Retail pharmacies with limited cold storage infrastructure don't hold large quantities of $3,000–$5,000 specialty injectables.

Low per-store dispensing volume makes routine stocking economically impractical.

Most Forteo is dispensed through specialty pharmacies (CVS Specialty, Walgreens Specialty, Accredo, Optum Specialty), not retail chains.

Prescribing Guidance: Brand vs. Generic

Generic teriparatide is FDA-approved and therapeutically equivalent to brand Forteo—same active ingredient, same 20 mcg dose, same subcutaneous injection route. The prefilled pen device may differ by manufacturer. Key clinical considerations:

Generic teriparatide is bioequivalent to Forteo and approved for the same indications

Some payers have moved generic to preferred/lower-tier status; verify formulary before prescribing

Prescribing as "teriparatide injection 20 mcg" (not DAW Forteo) allows generic substitution and may reduce PA burden for some patients

For patients on glucocorticoid-induced osteoporosis: generic teriparatide shares the same FDA-approved indication as brand Forteo

Prior Authorization Strategy for 2026

Prior authorization remains the most common access barrier. To minimize delays:

Submit PA the same day you write the prescription—don't wait for the pharmacy to generate a rejection

Include in the PA: DEXA T-scores, fracture history, bisphosphonate trial documentation (failure or intolerance), and clinical rationale for anabolic therapy

Many EHR systems have PA templates; build a standardized Forteo/teriparatide PA template to save staff time

If step therapy is required, document adequate bisphosphonate trial duration (typically 1 year) and reason for discontinuation (fracture on therapy, intolerance, or insufficient BMD response)

Clinical Alternatives If Teriparatide Remains Inaccessible

If insurance denial cannot be overturned or access barriers persist, consider:

Abaloparatide (Tymlos): Daily PTHrP analog; room temperature-stable for 30 days; comparable mechanism but no FDA approval for glucocorticoid-induced osteoporosis.

Romosozumab (Evenity): Dual anabolic/antiresorptive; monthly for 12 months; contraindicated with recent MI or stroke; often preferred if CV risk is acceptable.

Denosumab (Prolia): Antiresorptive only; good for patients who cannot do daily injections; requires ongoing therapy (fracture rebound risk on discontinuation).

Using medfinder for Providers

When patients need to start teriparatide urgently (e.g., following a recent fragility fracture) or their specialty pharmacy shipment is delayed, medfinder for Providers allows your practice to search for pharmacies near the patient that currently have teriparatide in stock. Giving patients a specific pharmacy name and address is far more actionable than telling them to "call around."